- Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial Reuters
- Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90% CNBC
- Moderna’s cancer shot: exciting for investors, inconclusive for patients Financial Times
- MRNA Stock Heads For Its Best Ever Day After Melanoma Therapy Meets Primary Goal Yahoo Finance
- Moderna shares surge as melanoma vaccine with Merck succeeds in large trial CNN